S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
New CBOE “special perk” helps traders target income every weekend (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
New CBOE “special perk” helps traders target income every weekend (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
New CBOE “special perk” helps traders target income every weekend (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
New CBOE “special perk” helps traders target income every weekend (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

$15.31
-0.58 (-3.65%)
(As of 12/8/2023 ET)
Compare
Today's Range
$15.12
$16.21
50-Day Range
$2.73
$108.00
52-Week Range
$2.73
$74.05
Volume
216,706 shs
Average Volume
2.93 million shs
Market Capitalization
$20.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VVOS stock logo

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

VVOS Stock Price History

VVOS Stock News Headlines

Black Swan: this small cap surged over 1000% last week
Vivos Therapeutics experienced a rare 'black swan' event, surging over 1000% in a single day following breaking news, here's how to look at VVOS stock now
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Why Is Vivos Therapeutics (VVOS) Stock Down 35% Today?
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Why Is Vivos Therapeutics (VVOS) Stock Up 290% Today?
Vivos Therapeutics closes $4M private placement
Vivos Therapeutics Closes $4 Million Private Placement
See More Headlines
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VVOS
Fax
N/A
Employees
154
Year Founded
N/A

Profitability

Net Income
$-23,840,000.00
Net Margins
-106.28%
Pretax Margin
-106.27%

Debt

Sales & Book Value

Annual Sales
$16.02 million
Book Value
$4.80 per share

Miscellaneous

Free Float
1,204,000
Market Cap
$20.36 million
Optionable
Not Optionable
Beta
8.80
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives















VVOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Vivos Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vivos Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VVOS shares.
View VVOS analyst ratings
or view top-rated stocks.

How have VVOS shares performed in 2023?

Vivos Therapeutics' stock was trading at $10.05 at the beginning of 2023. Since then, VVOS shares have increased by 52.3% and is now trading at $15.31.
View the best growth stocks for 2023 here
.

When is Vivos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our VVOS earnings forecast
.

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) posted its earnings results on Tuesday, November, 14th. The company reported ($1.75) EPS for the quarter. The company had revenue of $3.30 million for the quarter. Vivos Therapeutics had a negative trailing twelve-month return on equity of 508.27% and a negative net margin of 106.28%.

When did Vivos Therapeutics' stock split?

Vivos Therapeutics shares reverse split on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Vivos Therapeutics IPO?

(VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Who are Vivos Therapeutics' major shareholders?

Vivos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford K Amman and Ronald Kirk Huntsman.
View institutional ownership trends
.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:VVOS) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -